PD Dr. Jan Lehmann

2015

Rogler A, Kendziorra E, Giedl J, Stoehr C, Taubert H, Goebell PJ, Wullich B, Stöckle M, Lehmann J, Petsch S, Hartmann A, Stoehr R. Functional analyses and prognostic significance of SFRP1 expression in bladder cancer. J Cancer Res Clin Oncol. 141:1779-1790, 2015

Taubert H, Wach S, Jung R, Pugia M, Keck B, Bertz S, Nolte E, Stoehr R, Lehmann J, Ohlmann CH, Stöckle M, Wullich B, Hartmann A. Piwil 2 expression is correlated with disease-specific and progression-free survival of chemotherapy-treated bladder cancer patients. Mol Med. 21:371-380, 2015

2014

Rogler A, Hoja S, Giedl J, Ekici AB, Wach S, Taubert H, Goebell PJ, Wullich B, Stöckle M, Lehmann J, Petsch S, Hartmann A, Stoehr R. Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study. BMC Cancer. 14:214, 2014

2013

Keck B, Wach S, Stoehr R, Kunath F, Bertz S, Lehmann J, Stöckle M, Taubert H, Wullich B, Hartmann A: Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy. BMC Cancer 13:71, 2013

Saar M, Ohlmann CH, Siemer S, Lehmann J, Becker F, Stöckle M, Kamradt J. Fast-track rehabilitation after robot-assisted laparoscopic cystectomy accelerates postoperative recovery.
BJU Int 112:E99-106, 2013

Keck B, Wach S, Goebell PJ, Kunath F, Bertz S, Lehmann J, Stöckle M, Taubert H, Wullich B, Hartmann A: SNAI1 protein expression is an independent negative prognosticator in muscle-invasive bladder cancer. Ann Surg Oncol 20:3669-3674, 2013

Miller K, Hammerer P, Eichenauer R, Geiges G, Lehmann J, Rodemer G, Ruessel C, Rulf W, Suttmann H, Wolff JM: Stellenwert der intermittierenden Androgendeprivation im Kontext der aktuellen Datenlage. Aktuelle Urol 44:271-276, 2013

Keck B, Wach S, Kunath F, Bertz S, Taubert H, Lehmann J, Stöckle M, Wullich B, Hartmann A: Nuclear E-cadherin expression is associated with the loss of membranous E-cadherin, plasmacytoid differentiation and reduced overall survival in urothelial carcinoma of the bladder. Ann Surg Oncol 20:2440-2445, 2013

2011

Smith SC, Baras AS, Dancik G, Ru Y, Ding KF, Moskaluk CA, Fradet Y, Lehmann J, Stöckle M, Hartmann A, Lee JK, Theodorescu D: A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol. 12:137-143, 2011

Retz M, Rotering J, Nawroth R, Buchner A, Stöckle M, Gschwend JE, Lehmann J.: Long-term follow-up of bladder cancer patients with disseminated tumour cells in bone marrow. Eur Urol. 60:231-238, 2011

Nordentoft I, Dyrskjt L, Bdker JS, Wild PJ, Hartmann A, Bertz S, Lehmann J, Orntoft TF, Birkenkamp-Demtroder K.: Increased expression of transcription factor TFAP2 correlates with chemosensitivity in advanced bladder cancer. BMC Cancer. 11:135, 2011

Keck B, Stoehr R, Wach S, Rogler A, Hofstaedter F, Lehmann J, Montironi R, Sibonye M, Fritsche HM, Lopez-Beltran A, Epstein JI, Wullich B, Hartmann A.: The plasmacytoid carcinoma of the bladder - rare variant of aggressive urothelial carcinoma.
Int J Cancer. 129:346-354, 2011

Albers P, Park SI, Niegisch G, Fechner G, Steiner U, Lehmann J, Heimbach D, Heidenreich A, Fimmers R, Siener R; AUO Bladder Cancer Group.: Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol. 22:288-294, 2011

2010

Heidenreich A, Albers P, Classen J, Graefen M, Gschwend J, Kotzerke J, Krege S, Lehmann J, Rohde D, Schmidberger H, Uder M, Zeeb H: Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society. Urol Int 85:1-10, 2010

Nawroth R, Hartmann A, Wild P, Lehmann J, Stöhr R, Gschwend JE, Retz M: EMMPRIN (CD147) Ein prognostischer und potenzieller therapeutischer Marker im Urothelkarzinom. Pathologe Suppl 2, 251-254, 2010

Marschner N, Rüttinger D, Zugmaier G, Nemere G, Lehmann J, Obrist P, Bäuerle PA, Wolf A, Schmidt M, Abrahamsson PA, Reinhardt C, Heidenreich A: Phase II study of the human anti-epithelial cell adhesion molecule antibody Adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy. Urol Int 85:386-395, 2010

Hoffmann AC, Wild P, Leicht C, Bertz S, Danenberg KD, Danenberg PV, Stöhr R, Stöckle M, Lehmann J, Schuler M, Hartmann A: MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 12:628-636, 2010

J. Lehmann: Vinflunin in der Zweitlinienbehandlung des Urothelkarzinom. Der Onkologe 16:523-526, 2011

2009

Lehmann J, Suttmann H, Albers P, Volkmer B, Gschwend JE, Fechner G, Spahn M, Heidenreich A, Odenthal A, Seif C, Nürnberg N, Wülfing C, Greb C, Kälble T, Grimm MO, Fieseler CF, Krege S, Retz M, Schulte-Baukloh H, Gerber M, Hack M, Kamradt J, Stöckle M: Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol 55:1293-1299, 2009

Retz M, Gschwend JE, Lehmann J: Chemotherapie des Harnblasenkarzinoms - Neuigkeiten 2009. Urologe 48:655-662, 2009

Suttmann H, Kamradt J, Becker F, Lehmann J, Stöckle M: Das Ausmaß der Lymphadenektomie im Rahmen der radikalen Zystektomie - Fallstricke bei der Interpretation aktueller Studienergebnisse. Urologe. 48:151-155, 2009

Hartmann M, Siener R, Krege S, Schmelz H, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Weissbach L, Loy V, Wittekind C, Albers P; German Testicular Cancer Study Group: Ergebnisse der randomisierten Phase-III-Studie der German Testicular Cancer Study Group Retroperitoneale Lymphadenektomie vs. 1 Zyklus PEB als adjuvante Therapie beim nichtseminomatösen Hodentumor im klinischen Stadium I. Urologe 48:523-528, 2009

Lehmann J: Urothelkarzinom - Ursachen und Risikofaktoren. Uro-News: 49-54, 5/2009

Lehmann J, Suttmann H, Albers P, Volkmer B, Gschwend JE, Fechner G, Spahn M, Heidenreich A, Odenthal A, Seif C, Nürnberg N, Wülfing C, Greb C, Kälble T, Grimm MO, Fieseler CF, Krege S, Retz M, Schulte-Baukloh H, Gerber M, Hack M, Kamradt J, Stöckle M: Metastasenchirurgie in kurativer Absicht beim Urothelkarzinom. Urologe 48:143-150, 2009

2008

Albers P, Siener R, Krege S, Schmelz H-U, Dieckmann K-P, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann K-U, Fimmers R, Weißbach L, Loy V, Wittekind C, Hartmann M: Randomized Phase III Trial Comparing Retroperitoneal Lymph Node Dissection With One Course of Bleomycin and Etoposide Plus Cisplatin Chemotherapy in the Adjuvant Treatment of Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: AUO Trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 26:2966-2972, 2008

de Wit M, Brenner W, Hartmann M, Kotzerke J, Hellwig D, Lehmann J, Franzius C, Kliesch S, Schlemmer M, Tatsch K, Heicappell R, Geworski L, Amthauer H, Dohmen BM, Schirrmeister H, Cremerius U, Bokemeyer C, Bares R: [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol 19:1619-1623, 2008

Langbein S, Frederiks WM, zur Hausen A, Popa J, Lehmann J, Weiss C, Alken P, Coy JF: Metastasis is promoted by a bioenergetic switch: New targets for progressive renal cell cancer. Int J Cancer 122:2422–2428, 2008

Schulte-Baukloh H, Bigalke H, Miller K, Heine G, Pape D, Lehmann J, Knispel HH: Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure. Int J Urol. 15:407-415, 2008

Suttmann H, Grgic A, Lehmann J, Zwergel U, Kamradt J, Gouverneur E, Pinkert J, Stöckle M, Kirsch CM, Nestle U: Combining 153Sm-lexidronam and docetaxel for the treatment of patients with hormone-refractory prostate cancer: first experience. Cancer Biother Radiopharm. 23:609-618, 2008

Suttmann H, Retz M, Paulsen F, Harder J, Zwergel U, Kamradt J, Wullich B, Unteregger G, Stöckle M, Lehmann J: Antimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cells. BMC Urol. 3;8:5, 2008

Lehmann J: Medikamentöse Tumortherapie: Urothelkarzinom Fortschritte in der Neoadjuvanz, Adjuvanz und Palliation. Uro-News: 39-46, 6/2008

2007

Lehmann J, Suttmann H, Kovac I, Hack M, Kamradt J, Siemer S, Wullich B, Zwergel U, Stöckle M: Transitional cell carcinoma of the ureter: prognostic factors influencing progression and survival. Eur Urol 51:1281-1288, 2007

Stöckle M, Lehmann J, Krege S, Gschwend JE, Otto T, Rübben H: Therapie und Prognose des lymphogen metastasierten Harnblasenkarzinoms. Deutsches Ärzteblatt 104:959-963, 2007

Jakse G, Stöckle M, Lehmann J, Otto T, Krege S, Rübben H: Metastasiertes Harnblasenkarzinom. Deutsches Ärzteblatt 104:1024-1028, 2007

Suttmann H, Kamradt J, Lehmann J, Stöckle M: Improving the prognosis of patients after radical cystectomy. Part I: the role of lymph node dissection. BJU Int. 100:1221-1224, 2007

Suttmann H, Kamradt J, Lehmann J, Stöckle M: Improving the prognosis of patients after radical cystectomy. Part II: the role of perioperative chemotherapy. BJU Int. 100:1225-1228, 2007

Zwergel U, Suttmann H, Schröder T, Siemer S, Wullich B, Kamradt J, Lehmann J, Stöckle M: Outcome of prostate cancer patients with initial PSA> or =20 ng/ml undergoing radical prostatectomy. Eur Urol. 52:1058-1065, 2007

2006

Lehmann J, Franzaring L, Thüroff J, Wellek S, Stöckle M: Complete longterm survival data from a trial on adjuvant chemotherapy versus control after radical cystectomy for locally advanced bladder cancer, BJU Int 97:42-47, 2006

Lehmann J, Retz M, Sidhu SS, Suttmann H, Sell M, Paulsen F, Harder J, Unteregger G, Stöckle M: Antitumor activity of the antimicrobial peptide magainin II against bladder cancer cells. Eur Urol 50:141-147, 2006

Lehmann J, Retz M, Siemer S, Rotering J, Hack M, Schreier U, Zwergel U, Stöckle M: Long-term survival under maintenance gemcitabine chemotherapy for metastatic transitional cell carcinoma a case report. Int J Urol  13:1035-1036, 2006

Lehmann J, Retz M, Siemer S, Shayesteh-Kheslat R, Hack M, Stöckle M: Die Expression des antimikrobiellen Peptides MUC7 in der Pyelonephritis. Urologe 45:1300-1307, 2006

Lehmann J, Retz M, Stöckle M: Systemic chemotherapy for advanced transitional cell carcinoma: A critical analysis. In Trends in chemotherapy research. Weber MD (Hrsg.) Nova Science Publishers, Inc., 2006 (ISBN: 1-59454-353-4)

von der Maase H, Lehmann J, Gravis G, Joensuu H, Geertsen PF, Gough J, Chen G, Kania M:.A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. Ann Oncol 17:1533-1538, 2006

Jin JO, Lehmann J, Taxy J, Huo D, Stöckle M, Steinberg G, Stadler W: Phase II trial of adjuvant gemcitabine plus cisplatin with amifostine cytoprotection in patients with locally advanced bladder cancer. Clin Genitourin Cancer 5:150-154, 2006

Langbein S, Lehmann J, Harder A, Steidler A, Michel MS, Alken P, Badawi JK: Protein Profiling of Bladder Cancer Using the 2D-PAGE and SELDI-TOF-MS Technique. Technol Cancer Res Treat 5:67-72, 2006

2005

Lehmann J, Retz M, Wiemers C, Beck J, Throff J, Weining C, Albers P, Frohneberg D, Becker T, Funke PJ, Walz P, Langbein S, Reiher F, Schiller M, Miller K, Roth S, Kälble T, Sternberg D, Wellek S, Stöckle M: Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol 23:4963-4974, 2005

Lehmann J, Retz M, Stöckle M: Systemische Chemotherapie des metastasierten Urothelkarzinoms eine kritische Analyse; in Blasenkarzinom Neue Perspektiven in Diagnostik und Behandlung. Lehmann J, Retz M, Stöckle M (Hrsg). Springer Medizin Verlag Heidelberg, 2005 (ISBN: 3-540-20504-7)

Retz M, Lehmann J: Molekulare Prognosemarker des Harnblasenkarzinoms; in Blasenkarzinom Neue Perspektiven in Diagnostik und Behandlung. Lehmann J, Retz M, Stöckle M (Hrsg). Springer Medizin Verlag Heidelberg, 2005 (ISBN: 3-540-20504-7)

Stöckle M, Lehmann J: Das kontrovers diskutierte Tumorstadium pT1G3; in Blasenkarzinom Neue Perspektiven in Diagnostik und Behandlung. Lehmann J, Retz M, Stöckle M (Hrsg). Springer Medizin Verlag Heidelberg, 2005 (ISBN: 3-540-20504-7)

Stöckle M, Lehmann J: Therapie und Prognose des lymphogen metastasierten Urothelkarzinoms- Stellenwert der Lymphknotenchirurgie und der perioperativen systemischen Chemotherapie; in Blasenkarzinom Neue Perspektiven in Diagnostik und Behandlung. Lehmann J, Retz M, Stöckle M (Hrsg). Springer Medizin Verlag Heidelberg, 2005 (ISBN: 3-540-20504-7)

Siemer S, Lehmann J, Loch A, Becker F, Stein U, Schneider G, Ziegler M, Stöckle M: Current TNM classification of renal cell carcinoma evaluated: revising stage T3a. J Urol 173:33-37, 2005 
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration: Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Eur Urol 48:189-201, 2005

Lehmann J, Retz M, Stöckle M: Systemische Therapie des fortgeschrittenen Urothelkarzinoms. Der Onkologe 11:1210-1218, 2005

Lehmann J, Stöckle M: Adjunktive systemische Chemotherapie des lokal fortgeschrittenen Urothelkarzinoms der Harnblase. Journal ONKOLOGIE: 30-34, 5/2005

Lehmann J: Systemische Chemotherapie des lokal fortgeschrittenen Harnblasenkarzinoms adjuvante Behandlung 2005 im Blickpunkt. Uro-News: 35-37, 4/2005

Lehmann J, Böhle A: Studienlandschaft-Blasenkarzinom. Urologe 44:1435-1438, 2005

2004

Lehmann J, Retz M, Nrnberg N, Schnöckel U, Raffenberg U, Krams M, Kellner U, Siemer S, Weichert-Jacobsen K, Stöckle M: The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma. Cancer 101:1552-1562, 2004

Lehmann J, Stöckle M: Indication and results of adjuvant chemotherapy following radical cystectomy; in Current controversies in the management of genitourinary malignancies. Heidenreich A, Hofmann R, Ravery V (Hrsg) Sympomed Medical Publishers Taufkirchen /München, 2004 (ISBN: 3-927-75928-7)

Retz M, Lehmann J, Szysnik C, Zwank S, Venzke T, Wullich B, Röder C, Basbaum C, Stöckle M: Detection of occult tumor cells in lymph nodes from bladder cancer patients by MUC7 nested RT-PCR. Eur Urol 43:314-319, 2004

Zwergel U, Lehmann J, Wullich B, Schreier U, Remberger K, Zwergel T, Stöckle M: Lymph node positive prostate cancer: long-term survival data after radical prostatectomy J Urol 171:1128-1131, 2004

Siemer S, Lehmann J, Reinhard H, Graf N, Löffler G, Hendrik H, Remberger K, Stöckle M: Prenatal diagnosis of congenital mesoblastic nephroma associated with renal hypertension in a premature child. Int J Urol 11:50-52, 2004

Siemer S, Lehmann J, Kamradt J, Loch T, Remberger K, Humke U, Ziegler M, Stöckle M: Adrenal metastases in 1635 patients with renal cell carcinoma: outcome and indication for adrenalectomy. J Urol 171:2155-2159, 2004

2003

Lehmann V, Lehmann J: Die medizinische Versorgung der Toreros in Spanien. Zentralbl Chir 128:685-90, 2003

Lehmann J, Retz M, Steiner G, Albers P, Jaeger E, Knuth A, Lippert C, Koser M, Stockamp K, Otto C, Melchior H, Fassmann C, Potratz C, Loch T, Derigs HG, Becker T, Kälble T, Piechota HJ, Hertle L, Weinknecht S, Weissbach L, Al-Mwalad M, Hamza A, Henss H, Brkovic D, Pomer S, Roloff J, Walz P, Muschter R, Tunn U, Winter E, Bub P, Kaldenbach U, Roth S, Brauers A, Jakse G, Richter AE, Wirth M, Hartlapp J, Van Ahlen H, Stöckle M: Gemcitabin/Cisplatin versus MVAC 5-Jahres Ergebnisse der Phase III Studie zur Chemotherapie des fortgeschrittenen Urothelkarzinoms in Deutschland. UrologeA 42:1074-1086, 2003

Lehmann J, Retz M, Lippert C, Albers P, Stöckle M: Gemcitabin in der Behandlung des fortgeschrittenen Urothelkarzinoms. UrologeA 42:63-77, 2003

Lehmann J, Retz M, Stöckle M: Is there standard chemotherapy for metastatic bladder cancer? Quality of life and medical resources utilization based on largest to date randomized trial. Crit Rev Hemat Oncol 47:171-179, 2003

Lehmann J, Retz, M, Hack M, Siemer S, Stöckle M: Systemische Chemotherapie des Urothelkarzinoms. Onkologie 26(suppl 4):18-25, 2003

Retz M, Lehmann J, Amann E, Wullich B, Röder C, Stöckle M: Mucin 7 and cytokeratin 20 as new diagnostic urinary markers for bladder tumor. J Urol 169:86-89, 2003

2002

Lehmann J, Retz M, Harder J, Krams M, Kellner U, Hartmann J, Hohgräve K, Raffenberg U, Gerber M, Loch T, Weichert-Jacobsen K, Stöckle M: Expression of human beta-defensins 1 and 2 in kidneys with chronic bacterial infection. BMC Infect Dis 2:20, 2002

Lehmann J, Retz M, Siemer S, Kamradt J, Wullich B, Stöckle M: Managing locally advanced bladder cancer. Expert Rev Anticancer Ther 2:656-666, 2002

Lehmann J, Retz M, Stöckle M: Chemotherapy in the post-MVAC era, the case for adjuvant chemotherapy. World J Urol 20:144-150, 2002

Derouet H, Lehmann J, Stamm B, Lühl C, Römer D, Georg T, Isenberg E, Gebhardt T, Stöckle M: Age dependent secretion of LH and ACTH in healthy men and patients with erectile dysfunction. Eur Urol 41:144-153, 2002

Siemer S, Lehmann J, Humke U, Krenn T, Reinhard H, Graf N, Venzke T, Schneider G, Loch T, Stöckle M: Interdisziplinäres Therapiemanagement urogenitaler Rhabdomyosarkome im Kindesalter. Aktuel Urol 33:442-447, 2002

2001

Retz M, Lehmann J, Röder C, Weichert-Jacobsen K, Loch T, Romahn E, Lühl C, Kalthoff H, Stöckle M: Cytokeratin-20 reverse-transcriptase polymerase chain reaction as a new tool for the detection of circulating tumor cells in peripheral blood and bone marrow of bladder cancer patients. Eur Urol 39:507-517, 2001

Retz M, Lehmann J, Wullich B, Stöckle M: Nachsorge des Harnblasenkarzinoms. UrologeA 40:480-484, 2001

2000

Lehmann J, Retz M, Nürnberg N, Romahn E, Küppers F, Loch T, Stöckle M: Retroperitoneal mature teratoma fifteen years after initial treatment of testicular mixed germ cell tumor - a case report. Eur Urol 38:594-598, 2000

Lehmann J, Jancke C, Retz M, Loch T, Küppers F, Stöckle M, Weichert-Jacobsen K: A hypoechoic lesion found on testicular ultrasound after testicular piercing. J Urol 164:1651, 2000 

Retz M, Lehmann J, Trocha C, Loch T, Seppelt U, Fischer C, Pinkenburg F, Timm KJ, Wellek S, Stöckle M: Long-term followup of combined radiochemotherapy for locally advanced bladder cancer. Cancer 89:1089-1094, 2000

1999

Retz M, Lehmann J, Stöckle M: Systemische Chemotherapie des Harnblasenkarzinoms - Fakten und Entwicklungen seit 1998. UrologeB 39:317-320, 1999

1998

Retz M, Lehmann J, Röder C, Plötz B, Harder J, Eggers J, Pauluschke J, Kalthoff H, Stöckle M: Differential mucin MUC7 gene expression in invasive bladder carcinoma in contrast to uniform MUC1 and MUC2 gene expression in both normal urothelium and bladder carcinoma. Cancer Res 58:5662-5666, 1998

Retz M, Lehmann J, Stöckle M: Lokal fortgeschrittenes Urothelkarzinom der Harnblase. Was ist gesichert in der Uroonkologie. UrologeB 38:337-339, 1998 

1997

Lehmann J, Böck JC, Podrabsky P, Wlodarczyk W, Felix R: Young investigator award presentation at the 13th annual meeting of the ESMRMB, September 1996 Prag: Quantification of pulmonary water compartments by magnetic resonance. MAGMA 5: 3-11, 1997

Böck JC, Lehmann J: Kernspinangiographische Darstellung der experimentellen Lungenarterienembolie mit Hilfe eines makromolekularen Kontrastmittels. Röntgen Fortschr Geb Röntgenstr Neuen Bildgeb Verfahr 167: 516-520, 1997